Controlling new psychoactive substances in New Zealand

Autor: CS Johnson, Z Shadfar, JR Allison, KAJ Walsh, HK Partington

Publikováno v: Australian Journal of Forensic Sciences. :1-19

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b56d69862a8b13cf6b0496ebb924c60b
https://doi.org/10.1080/00450618.2022.2067230

Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions

Autor: Jf Desforges, Kenneth McIntosh, J Mccullough, Tl Wright, Kl Lindsay, Janet Wittes, Cf Whitsett, Rk Ross, Sm Lemon, Cs Johnson, Es Cooper, F Athari

Publikováno v: JAMA: The Journal of the American Medical Association. 274:1374-1379

Objective.-To provide physicians and other transfusion medicine professionals with a current consensus on infectious disease testing for blood transfusions. Participants.-A nonfederal, nonadvocate, 12-member consensus panel representing the fields of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6765a2bcc6fbd194e185de4d8c8f7a3
https://doi.org/10.1001/jama.274.17.1374

Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor

Autor: P Furmanski, CS Johnson

Publikováno v: Blood. 75:2328-2334

Macrophages have been shown to directly influence the growth and development of mature erythroid progenitors (CFU-E) in normal and erythroleukemic mice. We examined the mechanism by which macrophages mediate their effect on in vivo erythropoiesis. As

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8c7058ee1a3ff338fe7bcba9c726b7f
https://doi.org/10.1182/blood.v75.12.2328.bloodjournal75122328

American Society of Hematology: building a comprehensive minority recruitment and retention professional program.

Autor: Rollins MR; Department of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta, Atlanta, GA.; Department of Hematology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA., Warsame RM; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., Smith M; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Molina A; Clinical Development, Protagonist Therapeutics, Newark, CA., Rouce RH; Texas Children's Cancer Center, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Avalos BR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Johnson CS; Jane Anne Nohl Division of Hematology, Department of Medicine and of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, CA., Lopez JA; Division of Hematology, School of Medicine, University of Washington, Seattle, WA.; Bloodworks Northwest Research Institute, Seattle, WA., Thompson AA; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA., Fanning L; American Society of Hematology, Washington, DC., Frustace P; American Society of Hematology, Washington, DC., Roche K; American Society of Hematology, Washington, DC., van Havre N; American Society of Hematology, Washington, DC., Mack D; Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK., Flowers CR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Terrell DR; Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

Publikováno v: Blood advances [Blood Adv] 2024 Dec 24; Vol. 8 (24), pp. 6237-6247.

Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle.

Autor: Johnson CS; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom., Williams M; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Sham K; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Belluschi S; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Ma W; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Wang X; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Lau WWY; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Kaufmann KB; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Krivdova G; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Calderbank EF; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Mende N; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., McLeod J; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Mantica G; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Li J; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Grey-Wilson C; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Drakopoulos M; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Basheer S; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Sinha S; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Diamanti E; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Basford C; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom., Wilson NK; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Howe SJ; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom., Dick JE; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Göttgens B; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Green AR; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Francis N; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom.; Department of Gene Therapy and Regenerative Medicine, King's College London, London, United Kingdom., Laurenti E; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.

Publikováno v: Blood [Blood] 2024 Aug 15; Vol. 144 (7), pp. 729-741.